Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 2/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683169 | 0.98 | ADORA2A (0.46) | ADORA2AADORA2BESR1SLC22A12PDGFRA | |
| Fumaric Acid SCHEMBL5678076 | 0.89 | SLC22A12 (0.47) | ADORA2AADORA2BESR1SLC22A12PDGFRA | |
| SCHEMBL683164 | 0.86 | ADORA2A (0.43) | ADORA2AADORA2BESR1SLC22A12PDGFRA | |
| Ammonia Solution, Strong SCHEMBL1981730 | 0.82 | ADORA2A (0.45) | ADORA2AADORA2BESR1SLC22A12KHK | |
| SCHEMBL4507507 | 0.81 | GRM4 (0.43) | ADORA2AADORA2BESR1SLC22A12PDGFRA | |
| SCHEMBL21114013 | 0.80 | ADORA2A (0.46) | ADORA2AADORA2BESR1PDGFRACDK5 | |
| SCHEMBL7526015 | 0.78 | SLC22A12 (0.50) | SLC22A12KHKPTGDR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL906047 | 0.78 | HTR2C (0.51) | SLC22A12PDGFRACDK5TYRO3 | |
| Ammonia Solution, Strong SCHEMBL905946 | 0.78 | KIF11 (0.42) | ADORA2AADORA2BESR1SLC22A12ALDH1A1 | |
| SCHEMBL11977395 | 0.76 | SLC22A12 (0.67) | SLC22A12PTGDR2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1129078-B1 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY | VERNALIS RES LTD (GB) | 2006-03-15 | — | — | EP | claimed |
| US-6552062-B1 | For therapy of central nervous system disorders; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and obesity | VERNALIS RESEARCH LIMITED (GB) | 2003-04-22 | — | — | US | claimed |
| EP-1129078-A2 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY | VERNALIS RESEARCH LIMITED (GB) | 2001-09-05 | — | — | EP | claimed |
| WO-2000012481-A2 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY________________ | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| EP-1129078-B1 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY | VERNALIS RES LTD (GB) | 2006-03-15 | — | — | EP | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| US-6552062-B1 | For therapy of central nervous system disorders; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and obesity | VERNALIS RESEARCH LIMITED (GB) | 2003-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | ADORA2A 33/4885ADORA2B 31/4885ESR1 781/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | ADORA2A 33/4885ADORA2B 31/4885ESR1 781/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | ADORA2A 33/4885ADORA2B 31/4885ESR1 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.